Quantum BioPharma Ltd. (QNTM)Healthcare | Biotechnology | Toronto, Canada | NasdaqCM
3.12 USD
Short-term: ☆☆☆☆☆ | Long-term: ★★☆☆☆ | Dividends: ★☆☆☆☆ |
Hot Take | April 19, 2026, 12:06 a.m. EDT
The AI model indicates a high-conviction bearish swing (~ -22% downside) within 45 days despite a recent price recovery, driven by negative earnings, negative free cash flow, and a forward P/E indicating deeper losses; while the company maintains a 'No Going Concern' status and is pushing a Phase 2 MS drug forward, the balance sheet and valuation metrics point to a weak long-term hold with a token-like dividend potential. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.582209 |
| AutoETS | 0.656423 |
| AutoARIMA | 0.656427 |
| MSTL | 0.660078 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 63% |
| H-stat | 1.70 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.455 |
| Excess Kurtosis | 0.25 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 36.77 |
| Market Cap | 18,457,558 |
| Forward P/E | -0.40 |
| Beta | 0.29 |
| Previous Name | FSD Pharma Inc. |
| Website | https://www.quantumbiopharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.5031847 |
| Address1 | 55 University Avenue |
| Address2 | Suite 1003 |
| All Time High | 11,431.875 |
| All Time Low | 2.07 |
| Ask | 3.19 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 195,590 |
| Average Daily Volume3 Month | 321,834 |
| Average Volume | 321,834 |
| Average Volume10Days | 195,590 |
| Beta | 0.286 |
| Bid | 3.07 |
| Bid Size | 1 |
| Book Value | 1.781 |
| City | Toronto |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Canada |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.12 |
| Current Ratio | 1.069 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 3.2 |
| Day Low | 3.0501 |
| Debt To Equity | 36.77 |
| Display Name | Quantum BioPharma |
| Earnings Timestamp End | 1,755,520,200 |
| Earnings Timestamp Start | 1,755,001,800 |
| Ebitda | -14,756,594 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.076 |
| Enterprise Value | 15,877,221 |
| Eps Forward | -7.8 |
| Eps Trailing Twelve Months | -8.2 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.4925 |
| Fifty Day Average Change | -0.37250018 |
| Fifty Day Average Change Percent | -0.10665717 |
| Fifty Two Week Change Percent | -50.318466 |
| Fifty Two Week High | 38.25 |
| Fifty Two Week High Change | -35.13 |
| Fifty Two Week High Change Percent | -0.9184314 |
| Fifty Two Week Low | 2.07 |
| Fifty Two Week Low Change | 1.05 |
| Fifty Two Week Low Change Percent | 0.5072464 |
| Fifty Two Week Range | 2.07 - 38.25 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,528,464,600,000 |
| Float Shares | 5,362,516 |
| Forward Eps | -7.8 |
| Forward P E | -0.39999998 |
| Free Cashflow | -6,831,875 |
| Full Exchange Name | NasdaqCM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.2035 |
| Held Percent Institutions | 0.14166 |
| Implied Shares Outstanding | 5,915,884 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,723,680,000 |
| Last Split Factor | 1:65 |
| Long Business Summary | Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. It operates through two segments, Biopharmaceutical Innovation and Strategic Investments. The company researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse. In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is headquartered in Toronto, Canada. |
| Long Name | Quantum BioPharma Ltd. |
| Market | us_market |
| Market Cap | 18,457,558 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_266208867 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-20 |
| Net Income To Common | -26,175,286 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 17,861,012 |
| Number Of Analyst Opinions | 1 |
| Open | 3.15 |
| Operating Cashflow | -8,237,012 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 833 571 1811 |
| Pre Market Change | 0.16910005 |
| Pre Market Change Percent | 5.419873 |
| Pre Market Price | 3.2891 |
| Pre Market Time | 1,776,777,842 |
| Prev Name | FSD Pharma Inc. |
| Previous Close | 3.12 |
| Price Hint | 4 |
| Price To Book | 1.7518247 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.428 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 3.2 |
| Regular Market Day Low | 3.0501 |
| Regular Market Day Range | 3.0501 - 3.2 |
| Regular Market Open | 3.15 |
| Regular Market Previous Close | 3.12 |
| Regular Market Price | 3.12 |
| Regular Market Time | 1,776,715,200 |
| Regular Market Volume | 70,905 |
| Return On Assets | -0.67637 |
| Return On Equity | -3.46871 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 5,829,223 |
| Shares Percent Shares Out | 0.042600002 |
| Shares Short | 248,253 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 83,550 |
| Short Name | Quantum Biopharma Ltd. |
| Short Percent Of Float | 0.0475 |
| Short Ratio | 0.38 |
| Source Interval | 15 |
| State | ON |
| Symbol | QNTM |
| Target High Price | 12.787194 |
| Target Low Price | 12.787194 |
| Target Mean Price | 12.787194 |
| Target Median Price | 12.787194 |
| Total Cash | 2,364,437 |
| Total Cash Per Share | 0.406 |
| Total Debt | 1,876,211 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -8.2 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 11.216575 |
| Two Hundred Day Average Change | -8.096575 |
| Two Hundred Day Average Change Percent | -0.7218402 |
| Type Disp | Equity |
| Volume | 70,905 |
| Website | https://www.quantumbiopharma.com |
| Zip | M5J 2H7 |